Sagimet Biosciences (SGMT) Included in Russell 3000 Index

Sagimet Biosciences Inc. (NASDAQ: SGMT) was included in the Russell 3000 Index and the Russell 2000 Index during the June reconstitution, which includes approximately 4,000 of the largest U.S. companies by market capitalization. CEO David Happel noted this reflects the company's achievements and the expectations for its Phase 3 clinical study on denifanstat, which could become the first innovative oral treatment for acne vulgaris in over forty years if approved. The company has secured capital to fund its programs through 2028, including the upcoming clinical trial data readout. This inclusion may enhance Sagimet's visibility and appeal to investors, especially in the biopharmaceutical sector.